Contact
Home • Our expertise • Value, Pricing & Access

Value, Pricing & Access.

Build value and navigate the payer landscape.

Get in touch with a Value, Pricing & Access expert

What we do.

Combining rigorous science, payer, and healthcare system expertise, thorough strategic framing and analytics, and an ethos to pioneer, we can support you with evidence generation, HTA navigation, value, pricing, and access strategy, payer and channel contracting, and distribution strategy.

Our expertise across scientific and commercial domains delivers a collaborative and bespoke approach to maximize patient access and the commercial success of your innovations.

How we help.

With more than 250 professionals across 10 global office locations, our Value, Pricing and Access strategies bridge science and strategy to support you in delivering access for patients and realizing the value of your life-changing innovations.

We bring a rigorous and bespoke approach, relentlessly pursuing your objectives in true collaboration and partnership. Our team provides expertise and support across three key disciplines: Value, Pricing, and Access Strategy, HEOR Evidence Generation, and Evidence Synthesis and Real-World Evidence Generation.

Learn about our Centers of Excellence

Our Value, Pricing & Access Services.

Tap to view Value, Pricing & Access Strategy

Value, Pricing & Access Strategy

Value, Pricing & Access Strategy
Tap to view HEOR Evidence Generation

HEOR Evidence Generation

HEOR Evidence Generation
Tap to view Evidence Synthesis & RWE Generation

Evidence Synthesis & RWE Generation

Evidence Synthesis & RWE Generation

Case studies in related areas.

See how we’re helping clients solve key challenges and deliver on their ambitions.

More insights

Real-world evaluation of treatment patterns and resource utilization in Japanese patients with multiple myeloma using the MDV database

Putnam PHMR’s client needed a detailed description of multiple myeloma treatment patterns and resource utilization in Japanese patients..

Read more

Indirect treatment comparison (ITC) to generate comparative effectiveness evidence

A company was approaching the European market with evidence from a placebo-controlled RCT, but with several established competitors.

Read more

HTA evidence generation and preparedness for a novel oncology treatment

Our client needed successful HTA evidence packages and submissions to achieve reimbursement across Europe for an innovative oncology treatment.

Read more

Early value insights to drive value definition and evidence need to produce TrPP

The client wanted to understand the key drivers of value for the new treatment for sleep disorders including narcolepsy.

Read more

Our Value, Pricing and Access lead.

Eric Auger

Partner, VPA Practice Lead

Read bio

About Eric.

Eric leads Putnam’s Value, Pricing & Access global practice, which consists of over 250 market access strategy, HEOR and RWE professionals across 10 global offices. Prior to Putnam joining Inizio, Eric was Putnam’s Partnership Chair, coordinating firm strategy and governance. With over 27 years with Putnam, Eric has built deep expertise in market access strategy and supporting clients in navigating challenging payer, healthcare system, and competitive environments. He has supported clients across a wide range of therapeutic areas, modalities, and healthcare system sectors, with much of his work helping clients to pioneer new areas.

Latest thinking.

Get the latest insights and perspectives from our experts.

View all of our resources

Welcoming a new Principal and Partner to our team

We have recently welcomed two new Principals to join our team in Philadelphia and San Fransisco.

Read more

Welcoming new principals to our team

We have recently welcomed three new Principals to join our team across New York, Switzerland, and New Jersey.

Read more

Medicare price negotiation: Putnam’s round one picks

This paper outlines predictions regarding drugs likely to be impacted by Medicare Price Negotiation in 2026 and implications in subsequent years.

Read more

Distributional cost‑effectiveness analysis of treatments for non‑small cell lung cancer

Putnam aimed to conduct an aggregate DCEA of two NSCLC treatments recommended by NICE, and identify key drivers of the analysis.

Read more

Get in touch.

Looking to get in touch with an expert or team member?

Tell us how we can help.

Contact us today